Skip to main content

Table 1 Clinical characteristics of converted OMG and pure OMG

From: Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis

  Overall(58) Converted OMG (13) Pure OMG (45) p value
Gender, n (%) 0.300
 Male 24 (41.4%) 7 (53.8%) 17 (37.8%)  
 Female 34 (58.6%) 6 (46.2%) 29 (62.2%)  
Onset age (years), mean ± SD 55.1 ± 13.2 56.3 ± 10.6 54.4 ± 14.1 0.646
Ptosis, n (%) 0.448b
 Left 19 (32.8%) 4 (30.8%) 15 (33.3%)  
 Right 16 (27.6%) 2 (15.4%) 14 (31.1%)  
 Bilateral 23 (39.7%) 7 (53.8%) 17 (35.6%)  
Diplopia ( +), n (%) 25 (43.1%) 7 (53.8%) 18 (40.0%) 0.375
Anti-AchR Ab ( +), n (%) 40 (69.0%) 12 (92.3%) 28 (62.2%) 0.085
RNS ( +), n (%) 27 (46.6%) 11 (84.6%) 16 (35.6%) 0.002*
Disease duration before surgery (weeks), mean ± SD 19.3 ± 44.4 15.0 ± 27.1 20.5 ± 48.5 0.699
Surgical approach, n (%) 0.562b
 R/L-VATS 22 (37.9%) 4 (30.8%) 18 (40.0%)  
 TS 8 (13.8%) 3 (23.1%) 5 (11.1%)  
 Sub-xiphoid 28 (48.3%) 6 (46.2%) 22 (48.9%)  
Tumor location, n (%) 0.624b
 Left 23 (52.3%) 7 (58.3%) 16 (50.0%)  
 Right 19 (43.2%) 4 (33.3%) 15 (46.9%)  
 L + Ra 2 (4.5%) 1 (8.3%) 1 (3.1%)  
Maximum diameter (cm), mean ± SD 3.8 ± 1.6 3.5 ± 1.3 3.9 ± 1.7 0.441
Mean size (cm), mean ± SD 3.1 ± 1.2 2.8 ± 1.0 3.2 ± 1.3 0.351
Thymoma histotype + hyperplasia, n (%) 0.137b
 Thymoma  
  AB 10 (17.2%) 1 (7.7%) 9 (20.0%)  
  B1 4 (6.9%) 0 4 (8.9%)  
  B2 20 (34.5%) 7 (53.8%) 13 (28.9%)  
  B3 10 (17.2%) 4 (30.8%) 6 (13.3%)  
 Hyperplasia 14 (24.1%) 1 (7.7%) 13 (28.9%)  
 Thymoma: Hyperplasia 44:14 12:1 32:13 0.228
 B2 + B3: AB + B1 + hyperplasia 30:28 11:2 19:26 0.007*
Thymoma Stage + hyperplasia, n (%) 0.095b
 Thymoma  
  I 11 (19.0%) 4 (30.8%) 7 (15.6%)  
  IIa 12 (20.7%) 1 (7.7%) 11 (24.4%)  
  IIb 13 (22.4%) 3 (23.1%) 10 (22.2%)  
  III 8 (13.8%) 4 (30.8%) 4 (8.9%)  
 Hyperplasia 14 (24.1%) 1 (7.7%) 13 (28.9%)  
NTOMG, n (%) 1.000b
 Early-onset (age ≤ 50) 7 (12.1%) 0 7 (15.6%)  
 Late-onset (age > 50) 7 (12.1%) 1 (7.7%) 6 (13.3%)  
Post-operative prednisone ( +), n (%) 20 (34.5%) 4 (30.8%) 16 (35.6%) 1.000
Post-operative follow-up duration (months), mean ± SD 59.3 ± 30.3 55.5 ± 36.3 60.5 ± 28.8 0.608
  1. Values in boldface as well as * indicate statistically significant
  2. OMG ocular myasthenia gravis, NTOMG non-thymomatous OMG, AChR-ab anti-acetylcholine receptor antibody, RNS repetitive nerve stimulation, R/L-VATS right/left-video assisted thoracoscopic surgery, TS trans-sternal
  3. *Statistically significant
  4. aTumor boundary exceeds both sides of sternal border
  5. bFisher exact test